Plain-English translation of NCT05122806 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying what happens inside tumors and in the bloodstream of people with advanced lung cancer caused by an ALK gene rearrangement who are being treated with newer ALK-targeted medications like alectinib or brigatinib. By analyzing tumor tissue samples and blood samples taken at different points in treatment, scientists hope to better understand how these cancers respond to the medication and what changes occur if the cancer stops responding.
Doctors need better ways to predict which patients will benefit most from these medications and to understand what happens when cancers become resistant to treatment, so they can develop even more effective strategies in the future.
You likely qualify if…
You likely don't qualify if…
If you join, researchers will collect tumor tissue from your initial diagnosis and may collect additional tissue if you have a biopsy when your cancer progresses. You will also give blood samples at three key times: when you start the medication, at your first follow-up scan or evaluation, and if your cancer advances. These samples will be sent to a central lab in Lyon to analyze how your tumor's genetic makeup is changing and how it responds to the medication over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France